{"url_path":"/sec/cgtx/8-k/2026-06-24/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-077060-index.html","accession_number":"0001104659-26-077060","cik":"0001455365","ticker":"CGTX","issuer_name":"COGNITION THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-077060-index.html","primary_entity_key":"0001455365","primary_entity_name":"COGNITION THERAPEUTICS INC"},"word_count":65,"has_tables":true,"body_markdown":"**Item 8.01 Results of Operations and Financial Condition.**\n\n \n\nOn June 24, 2026, Cognition\nTherapeutics, Inc. (the “Company”) issued a press release announcing the receipt of written feedback from the U.S. Food and\nDrug Administration (the “FDA”) following the Company’s recent meeting with the FDA in May. A copy of the Company’s\npress release is filed as Exhibit 99.1 to this Current Report on Form 8-K."}